Abstract 907P
Background
Adenoid cystic carcinoma (ACC) is characterized by multiple relapses and a poor prognosis. It is commonly considered a radioresistant tumor, indeed particle radiotherapy is especially indicated in ACC. Recently, ACC was stratified in two clusters with a different prognosis, ACC type I and II, according to distinct molecular features i.e. NOTCH activating mutation and TP63 upregulation, respectively. We aimed to disclose molecular profiles predictive of radiosensitivity or radioresistance features.
Methods
The study cohort comprised 54 patients with ACC of salivary gland origin, treated with surgery plus photon beam radiotherapy (R) or R alone. A survey in the literature yielded a list of 15 signatures including pan-cancer or different tumor-specific models (e.g. head and neck; breast cancer; glioblastoma; prostate cancer) with a total of 141 genes. The expression levels of these genes were retrieved and signatures scores were imputed following the methods described in the original papers. Log2-trasformed transcripts per million mapped reads values were retrieved from Ferrarotto et al. [PMC7854509]. Clinical and follow-up data were updated at 31st December 2022; overall survival (OS) as endpoint was estimated with the Kaplan-Meier method.
Results
Only the signatures developed on breast cancer gene-expression datasets among those investigated were able to stratify ACC patients; in particular, we focused on an immune-radiosensitivity signature [PMC8984882] able to reach HR=7.59, 95%CI 3.19-18.09, p=1e-07. The predicted radiosensitivity of this signature was significantly associated with ACC type II and lack of NOTCH mutations.
Conclusions
Molecular profile of ACC type II is significantly associated with an intrinsic radiosensitivity. The association of ACC radiosensitivity to breast cancer signatures warrants further research on the biology behind ACC and its molecular similarities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12